Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.3%

662 terminated/withdrawn out of 3262 trials

Success Rate

67.0%

-19.5% vs industry average

Late-Stage Pipeline

4%

142 trials in Phase 3/4

Results Transparency

63%

849 of 1343 completed trials have results

Key Signals

552 recruiting849 with results431 terminated231 withdrawn

Enrollment Performance

Analytics

Phase 2
1109(41.3%)
Phase 1
814(30.3%)
N/A
547(20.4%)
Phase 3
108(4.0%)
Early Phase 1
75(2.8%)
Phase 4
34(1.3%)
2687Total
Phase 2(1109)
Phase 1(814)
N/A(547)
Phase 3(108)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3262)

Showing 20 of 3262 trials
NCT04789681Phase 2Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Role: lead

NCT06261060Phase 2Active Not Recruiting

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Role: lead

NCT04493164Phase 2Recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Role: lead

NCT00329043Phase 2Active Not Recruiting

Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy

Role: lead

NCT05834244Phase 1Recruiting

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Role: lead

NCT04729322Phase 2Active Not Recruiting

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

Role: lead

NCT00488072Phase 2Active Not Recruiting

Effects of Mirtazapine on Appetite in Advanced Cancer Patients

Role: lead

NCT05475171Phase 2Suspended

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Role: lead

NCT02479698Phase 2Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Role: lead

NCT00991094Recruiting

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy

Role: lead

NCT04505254Phase 2Active Not Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Role: lead

NCT04616183Phase 1Active Not Recruiting

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

Role: lead

NCT00929214Phase 2Active Not Recruiting

Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients

Role: lead

NCT01154920Phase 2Active Not Recruiting

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: lead

NCT05226663Phase 2Active Not Recruiting

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Role: lead

NCT05804227Early Phase 1Recruiting

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

Role: lead

NCT04592237Phase 2Active Not Recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Role: lead

NCT06184321Early Phase 1Recruiting

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Role: lead

NCT05132296Not ApplicableActive Not Recruiting

Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer

Role: lead

NCT05873192Phase 2Recruiting

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Role: lead